At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Varenicline +1 moredrug
Likely dose
Varenicline 1.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Human Behavioral Pharmacology Laboratory (HBPL) Study of Varenicline's Impact on Cocaine and Alcohol Craving
In Brief
A Phase 2 clinical trial evaluating Varenicline and Placebo for Alcohol Dependence and Cocaine Dependence. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This is a Phase II within-subjects double-blind placebo-controlled human laboratory study. The purpose of the study is to determine the efficacy of varenicline (Chantix) for reducing cue-induced cocaine and alcohol craving.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Dependence, Cocaine Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartJul 2010
Primary CompletionAug 2013
Study CompletionDec 2013
TodayJul 2026
First PostedJun 28, 2010
Enrollment StartJul 1, 2010
Primary CompletionAug 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 16.0 years ago
Interventions
Vareniclinedrug
Varenicline, oral target dose of 1.0 mg BID, one week titration.
Placebodrug
Placebo